| pubmed-article:8482853 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8482853 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8482853 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:8482853 | lifeskim:mentions | umls-concept:C0063710 | lld:lifeskim |
| pubmed-article:8482853 | lifeskim:mentions | umls-concept:C1415900 | lld:lifeskim |
| pubmed-article:8482853 | lifeskim:mentions | umls-concept:C0175630 | lld:lifeskim |
| pubmed-article:8482853 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:8482853 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8482853 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:8482853 | pubmed:dateCreated | 1993-6-3 | lld:pubmed |
| pubmed-article:8482853 | pubmed:abstractText | This study was undertaken to determine whether IFN induce IL-1 receptor antagonist (IL-1Ra), a specific inhibitor of IL-1. Plasma samples were obtained from healthy volunteers (n = 5) and patients with chronic hepatitis C (n = 5) treated with IFN-alpha, and from patients with renal cell carcinoma (n = 6) treated with IFN-gamma and assayed for IL-1Ra by a specific radioimmunoassay. Both types of IFN were administered subcutaneously. In vitro studies were carried out with PBMC from healthy volunteers. A single, low and nontoxic dose (1 x 10(6) U) of IFN-alpha induced circulating IL-1Ra, which reached peak levels within 12 h. This effect was dose-dependent and more pronounced with a higher dose (5 x 10(6) U). Peak IL-1Ra levels 12 h after 5 x 10(6) U IFN-alpha were 4.16 +/- 0.35 ng/ml in healthy volunteers and 5.7 +/- 0.73 ng/ml in patients with chronic hepatitis C (difference not significant). Thereafter levels declined but remained elevated for 24 h. IFN-gamma treatment led only to a modest increase of circulating IL-1Ra even at a dose of 400 micrograms; this dose, however, was associated with side effects similar to those seen after injection of 5 x 10(6) U IFN-alpha. PBMC stimulated with IFN-alpha or IFN-gamma produced IL-1Ra in vitro. The induction of IL-1Ra may contribute to the antiviral, anti-inflammatory, and antiproliferative effects of IFN. | lld:pubmed |
| pubmed-article:8482853 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8482853 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8482853 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8482853 | pubmed:month | May | lld:pubmed |
| pubmed-article:8482853 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:VogelWW | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:DinarelloC... | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:HuberCC | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:TillMM | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:WiedermannC... | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:MierJ WJW | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:AulitzkyW EWE | lld:pubmed |
| pubmed-article:8482853 | pubmed:author | pubmed-author:VannierEE | lld:pubmed |
| pubmed-article:8482853 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8482853 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8482853 | pubmed:volume | 150 | lld:pubmed |
| pubmed-article:8482853 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8482853 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8482853 | pubmed:pagination | 4687-92 | lld:pubmed |
| pubmed-article:8482853 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:meshHeading | pubmed-meshheading:8482853-... | lld:pubmed |
| pubmed-article:8482853 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8482853 | pubmed:articleTitle | Induction of circulating IL-1 receptor antagonist by IFN treatment. | lld:pubmed |
| pubmed-article:8482853 | pubmed:affiliation | Department of Medicine, New England Medical Center Hospitals, Boston, MA 02111. | lld:pubmed |
| pubmed-article:8482853 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8482853 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8482853 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8482853 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8482853 | lld:pubmed |
